Focal Therapy

with Fusion-Guided Laser Ablation

Precise Treatment. Precise Results.

Focal laser ablation provides a minimally invasive treatment that targets and ablates (destroys) only specific parts of glands, organs, or other tissue needing treatment, while preserving the surrounding and remaining tissue. This generally produces faster recovery, fewer side effects, and less pain and discomfort for patients that may not be good candidates or are inoperable for traditional open surgery*.

About CLS

CLS is an innovative company within healthcare technology and therapy. With people in mind, we are at the forefront of developing more precise, more effective interventional healthcare solutions. 

Our TRANBERG™ systems are approved and marketed in the US and Europe providing minimally invasive alternatives to traditional treatments. 

Focal therapy using TRANBERG™ Thermal Therapy System

Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally, without damaging healthy tissue.

Patient Focused

  • Minimally invasive office outpatient procedure.
  • Low risk of complications – minimal blood loss, low risk of infections, low pain.
  • Minimized risk of erectile dysfunction and urinary incontinence.
cart02-fix-220906

A high precision laser ablation system for successful Focal Therapy

Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed the TRANBERG™ Thermal Therapy System for US Fusion-guided focal laser ablation.

  • Precise positioning of the laser applicator in the defined target area using MRI-US fusion for real-time image-guidance.
  • Temperature control during the procedure.
  • Option to choose between transperineal and transrectal pathway access.
  • Targeted tissue destruction.
  • Surrounding, non-cancerous tissue is spared.

How it all started

Through research by our co-founder, professor Karl-Göran Tranberg, CLS has gained significant knowledge and experience with treating/killing cancer tumors using laser ablation under image guidance. 

Today, our TRANBERG™ Thermal Therapy System is optimized for minimally invasive focal therapy of soft tissue and used to treat patients with localized prostate cancer. 

focal-therapy

Michael Magnani, President of CLS Americas, about our history
and the TRANBERG products

News and insights

21 December, 2022

Christmas greeting from CLS - We wish you all a very Happy Holiday season and look forward to a tremendous 2023!

At CLS we can look back on an exciting year where we have made significant progress towards our vision that laser ablation will be introduced as standard treatment in focal therapy and as an alternative to traditional surgery and, in the longer term, as a complementary systemic treatment of metastasized cancer.

Read more
28 November, 2022

Clinical data from a Phase II trial using CLS TRANBERG products presented during RSNA 2022 Annual Meeting

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

Read more
2 November, 2022

Interview with our CTO and VP Clinical Affairs – How CLS contributes to better treatment of Prostate Cancer

Our CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik, explain how the TRANBERG® Thermal Therapy Systems have been designed for precise and safe focal therapy of soft tissue, such as the prostate gland, and what kind of research CLS is now supporting.

Read more

*All the focal therapies report low rates of complications, and high rates of continence and erectile function preservation. Klotz et al. Curr Opin Urol. (2020).  

Sign up for our
newsletter

Make sure you get all the exciting information about CLS’ progress on an ongoing basis.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US